LPCAT2BP

Across TCGA pan-cancer cohorts, LPCAT2BP RNA is linked to patient survival in 10 of 34 cancer types, making it the most broadly survival-associated LPCAT2BP data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LPCAT2BP RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LPCAT2BP expression acts as an unfavorable survival marker, although some lineages such as ESCA and COAD show a favorable association.

LIHC, DLBC, and LUSC are the cancer types where LPCAT2BP RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	III,IV	0.085	0.364	.001	45	view →
DLBC	OS	Tertile	III,IV	0.154	0.735	.010	40	view →
LUSC	OS	Tertile	All	0.208	0.527	.011	30	view →
LUAD	OS	Tertile	IV	0.114	0.560	.038	18	view →
SKCM	OS	Tertile	All	0.654	0.877	.002	15	view →
ESCA	OS	Median	IV	0.698	0.222	.006	12	view →
COAD	DFS	Tertile	All	0.814	0.673	.035	9	view →
MESO	DFS	Tertile	All	1.000	0.194	.046	3	view →
KIRP	OS	Tertile	All	0.822	0.938	.047	3	view →
STAD	OS	Quartile	IV	0.722	0.312	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

LPCAT2BP–LIHC (DFS)

Open the LIHC breakdown →